Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Healthtrust
Queensland Health
Cipla
Fuji
Mallinckrodt
Chubb
Julphar
UBS

Generated: February 25, 2018

DrugPatentWatch Database Preview

Rufinamide - Generic Drug Details

« Back to Dashboard

What are the generic sources for rufinamide and what is the scope of rufinamide freedom to operate?

Rufinamide
is the generic ingredient in two branded drugs marketed by Eisai Inc, Glenmark Pharms Ltd, Mylan Pharms Inc, and West-ward Pharms Int, and is included in five NDAs. There are three patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for rufinamide. One supplier is listed for this compound.

US Patents and Regulatory Information for rufinamide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-003 Nov 14, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
West-ward Pharms Int RUFINAMIDE rufinamide TABLET;ORAL 204988-001 May 16, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glenmark Pharms Ltd RUFINAMIDE rufinamide TABLET;ORAL 205075-001 May 16, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glenmark Pharms Ltd RUFINAMIDE rufinamide TABLET;ORAL 205075-002 May 16, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-003 Nov 14, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
US Department of Justice
McKinsey
Moodys
Fuji
Cerilliant
Teva
Merck
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot